Cannara Biotech's Days Sales Outstanding for the
three
months ended in Feb. 2026 was 46.31.
Cannara Biotech's Days Inventory for the
three
months ended in Feb. 2026 was 310.65.
Cannara Biotech's Days Payable for the
three
months ended in Feb. 2026 was 70.63.
Therefore, Cannara Biotech's Cash Conversion Cycle (CCC) for the
three
months ended in Feb. 2026 was 286.33.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Cannara Biotech Cash Conversion Cycle Related Terms
Cannara Biotech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8CB0 vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Cannara Biotech's Cash Conversion Cycle for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (FRA:8CB0) has a Cash Conversion Cycle of 286.33 as of Feb. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Cash Conversion Cycle too high?
Cannara Biotech's current Cash Conversion Cycle is 286.33. The Drug Manufacturers industry median Cash Conversion Cycle is 145.92. Cannara Biotech's value of 286.33 is 96.2% above this industry median. Overall, Cannara Biotech has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Cash Conversion Cycle compare to ZTS and UTHR?
Cannara Biotech's Cash Conversion Cycle of 286.33 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.92. Cannara Biotech's value of 286.33 is 96.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.92, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Cash Conversion Cycle of 286.33 is 96.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Cash Conversion Cycle is 286.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (FRA:8CB0) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.00, compared to a current price of €1.08 — trading 8% above its estimated fair value. The current Cash Conversion Cycle is 286.33 and 96.2% above the Drug Manufacturers industry median of 145.92. Cannara Biotech's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Cannara Biotech (FRA:8CB0), the current Cash Conversion Cycle is 286.33 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (FRA:8CB0) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of €1.08 is trading 8% above its estimated GF Value™ of €1.00.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for FRA:8CB0:
Cash Conversion Cycle: 286.33
GF Value™: €1.00 vs. price of €1.08 (8% above fair value)
Industry Position: 96.2% above the Drug Manufacturers median
No single metric tells the full story. See the FRA:8CB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
62GF Score
Get the complete analysis for FRA:8CB0
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8CB0 has been successfully added to your 
